Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 12, Issue 7, Pages 883-903Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.7.883
Keywords
autoimmune disease; BTK; Bruton's tyrosine kinase; common gamma; chain; cytokines; delayed-type hypersensitivity; dry eye; DTH; inflammation; IRAK-4; JAK-3; Janus kinase; p38; PKC theta; psoriasis; rheumatoid arthritis; rho kinase; SCID; severe combined immunodeficiency; STAT; signal transducers and activators of transcription; TYK; Tyrosine kinase gamma c; XID; X-linked immunodeficiency; XLA; X-linked agammaglobulinemia
Categories
Ask authors/readers for more resources
At the time of writing, there are seven marketed kinase inhibitor drugs. The first kinase inhibitor, imatinib mesilate (Gleevec (R), Novartis), came to market in 2001, an inhibitor of the breakpoint cluster region (BCR)/Abelson murine leukemia oncogene homolog (ABL) fusion, platelet-derived growth factor (PDGF) receptor, and c-kit kinases. The most recent kinase inhibitor to come to market, disatinib (Sprycel (R), Bristol-Myers Squibb), acts on c-SRC, ABL and Bruton's tyrosine kinase. To date, kinase inhibitor drugs are approved for oncology and demonstrate that it is possible to develop compounds with relative selectivity for the target kinase against the broader kinome. However, the use of kinase inhibitors in chronic inflammatory and immunologic diseases may require greater selectivity for the target kinase. This review addresses the opportunities and challenges of kinase inhibition as a therapeutic approach in chronic immune and inflammatory disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available